Advances in phase Ⅲ drug studies on the pipeline in nonalcoholic steatohepatitis
10.3969/j.issn.1001-5256.2022.06.037
- VernacularTitle:非酒精性脂肪性肝炎在研Ⅲ期临床试验新药研究进展
- Author:
Yu WANG
1
;
Xuebing YAN
1
Author Information
1. Department of Infection and Liver Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, China
- Publication Type:Reviews
- Keywords:
Nonalcoholic Steatohepatitis;
Therapeutics;
Clinical Trial, Phase Ⅲ
- From:
Journal of Clinical Hepatology
2022;38(6):1398-1401
- CountryChina
- Language:Chinese
-
Abstract:
Nonalcoholic steatohepatitis (NASH) can cause end-stage liver diseases such as liver cirrhosis and liver cancer, and therefore, it is urgent to treat NASH, reverse hepatic steatosis, and delay the onset of end-stage liver diseases. NASH has a complex pathogenesis and there are currently no effective drugs for treatment. At present, new drugs still have huge market potential and are the research hotspots of various pharmaceutical companies in China and globally. This article mainly reviews and summarizes the clinical research status, drug types, mechanism of action, and future market prospects of the new drugs for NASH in existing phase Ⅲ studies.
